Important Safety Information | NIOX VERO® User Manual (PDF)

For Healthcare Professionals Only

EN

Partner Portal

For questions about coronavirus/COVID-19 and using NIOX VERO®, please visit the NIOX VERO Coronavirus/COVID-19 FAQ.

Publications & Whitepapers

Recent Noteworthy Publications

Clinical Studies

Alving K et al. Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma. Pulm Ther. 2017 3(1):207-218.

Anderson, WJ, Short, PM, Jabbal, S, Lipworth, BJ. Inhaled corticosteroid dose response in asthma. Should we measure inflammation? Ann Allergy Asthma Immunol 2017; 118:179e185.

Coumou H, Westerhof GA, de Nijs SB, et al. Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J. 2018; 51: 1701785.

Hanania N, Massanari M, Jain N. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018;120: 414–418.

Karrasch S, Linde K, Rücker G, et al. Accuracy of FeNO for diagnosing asthma: a systematic review. Thorax 2017; 72:109–116.

LaForce C, Brooks E, Herje N, Dorinsky P, Rickard K. Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic. Ann Allergy Asthma Immunol. 2014;113(6):619–623.

Morten M, Collison A, Murphy VE, et al. Managing Asthma in Pregnancy (MAP) trial: FeNO levels and childhood asthma. J Allergy Clin Immunol 2018; 142(6):1765-1772.

Peirsman EJ, Carvelli TJ, Hage PY, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol. 2014;49(7):624–631.

Price D, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med. 2018;6(1):29–39.

Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med. 2004;169(4):473–478.

Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med. 2005;172(4):453–459.

Syk J et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. J Allergy Clin Immunol Pract. 2013 1(6):639-48.

Cost Effectiveness

Arnold RJ, Massanari M, Lee TA, Brooks E. A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Manag Care. 2018 Jul;27(7):34-41.

Arnold RJG, Layton A, Massanari M. Cost impact of monitoring exhaled nitric oxide in asthma management. Allergy Asthma Proc. 2018;39(5):338–344.

Brooks EA, Massanari M. Cost-Effectiveness Analysis of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in the Management of Asthma. Manag Care. 2018;27(7):42-48.

Evidence Reviews

Carroll WD. NIOX VERO: Individualized asthma management in clinical practice. Pulm Ther 2016; 2:171-188.

Maniscalco M, Vitale C, Vatrella A, Molino A, Bianco A, Mazzarella G. Fractional exhaled nitric oxide-measuring devices: technology update. Med Devices (Auckl). 2016;9:151–160.

Pavord ID, Beasley R, Agusti A, et al. After Asthma: Refining Airways Diseases. Lancet. 2018;391(10118):350–400.

Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110–1119.

Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database of Systematic Reviews. 2016;9(9):CD011440.

Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database of Systematic Reviews. 2016;11(11):CD011439.

Wang Z, Pianosi P, Keogh K, et al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017.

Guidelines

Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2018 Update. 2018.

An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011 184(5):602-15.

National Institute for Health and Clinical Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline [NG80]. 2017.

National Institute for Health and Clinical Excellence (NICE). Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath. NIOX Diagnostics guideline [DG12]. 2014.

Whitepapers

Summary of Evidence Supporting the Clinical Value of Monitoring Exhaled Nitric

Circassia White Paper. Summary of Evidence Supporting the Clinical Value of Monitoring Exhaled Nitric Oxide (FeNO) in the Management of Asthma. Circassia Pharmaceuticals, Inc. May 2018.

Asthma management is supported by national guidelines that were initially created to emphasise the importance of treating the inflammatory nature of the disease to improve patient outcomes (NHLBI 1991). Today, FeNO (fractional exhaled nitric oxide) is a well-established, validated and specific biomarker for T2 driven airway inflammation in asthma 20 years after the Nobel Prize was awarded in 1998 for understanding the importance of nitric oxide in the cardiovascular system.